Novartis brands sickle cell results an example of 'reimagining medicine'

11 October 2018

A post-hoc analysis of the SUSTAIN study of crizanlizumab, Novartis’ (NOVN: VX) humanized anti-P-selectin monoclonal antibody being investigated for the treatment of sickle cell disease (SCD), have been presented ahead of an expected US filing in 2019.

The Phase II study analysis has been published in the American Journal of Hematology. It shows that more patients given crizanlizumab did not experience a vaso-occlusive crisis (VOC) compared to those treated with placebo (35.8% versus 16.9%), specifically patients with a history of two to 10 VOCs in the previous year.

VOCs are a painful complication of SCD and the main reason for hospitalization. Currently, treatment options for VOCs are limited.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK